Development of a new CKD therapy aimed for renoprotection by renal PPARalpha activation

Research Project

Project/Area Number	25460329
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	General pharmacology
Research Institution	Shinshu University
Principal Investigator	KAMIJO Yuji 信州大学, 学術研究院医学系(医学部附属病院), 准教授 (50377636)
Co-Investigator(Kenkyū-buntansha)	AOYAMA Toshifumi 信州大学, 学術研究院医学系, 教授 (50231105)
Project Period (FY)	2013-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000) Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords	腎保護 / 脂肪酸 / ペルオキシソーム増殖剤活性化受容体 / 炎症 / 酸化ストレス / アンギオテンシンⅡレセプター拮抗薬 / ＰＰＡＲα / ＡＲＢ / イルベサルタン / 慢性腎臓病 / 尿細管 / 蛋白尿 / 脂肪酸代謝
Outline of Final Research Achievements	This study aimed to establish the safe PPARα agonist which is usable in chronic kidney disease situation. This study demonstrated that an angiotensin II receptor antagonist Irbesartan activates renal PPARα, and exerts renoprotective effects in murine protein overload nephropathy model. These findings would be useful to develop novel therapeutic strategy against chronic kidney disease.